ArticleJournal of ovarian research2026
Dual action of SS31 via NRF2/HO-1: countering oxidative stress and metabolic dysfunction in ovarian aging.
Article in Journal of ovarian research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundThe global trend of delayed childbearing underscores age-related fertility decline as a critical health issue, driven primarily by the loss of ovarian follicles. Mitochondrial dysfunction and oxidative stress are key pathological factors in this process. SS31, a mitochondria-targeting antioxidant peptide, holds potential for mitigating reproductive aging, though its precise mechanisms in ovarian aging require further elucidation.
methodsThis preclinical study utilized a naturally aged (10-month-old) female ICR mouse model and a D-galactose-induced senescence model in human KGN granulosa cells. We investigated the protective effects and mechanism of action of SS31 on the ovarian follicle unit.
resultsSS31 specifically localized to granulosa cell mitochondria. Treatment alleviated oxidative damage-induced apoptosis, improved mitochondrial function (including membrane potential and ATP production), and ameliorated senescence-associated impairment of the granulosa cell-oocyte unit. Mechanistically, SS31 enhanced cellular antioxidant capacity by activating the NRF2/HO-1 signaling pathway.
conclusionThis study demonstrates that SS31 preserves ovarian function by improving mitochondrial performance and redox homeostasis via the NRF2/HO-1 axis. These findings provide a solid theoretical and experimental foundation for the potential application of SS31 in delaying ovarian aging and treating related reproductive disorders, such as premature ovarian insufficiency (POI) and polycystic ovary syndrome (PCOS), highlighting its significant translational value.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.